证券代码：301263 证券简称：泰恩康 公告编号：2025-059 广东泰恩康医药股份有限公司 本公司及董事会全体成员保证公告内容的真实、准确和完整，没有虚假 记载、误导性陈述或者重大遗漏。 特别提示： 一、会议召开和出席情况 （一）会议召开时间： （1）通过深圳证券交易所交易系统进行网络投票的具体时间为：2025 年 8 月 20 日 9:15-9:25，9:30-11:30，13:00-15:00； （2）通过深圳证券交易所互联网投票系统投票的具体时间为：2025 年 8 月 （二）召开地点：广东省汕头市龙湖区泰山北路万吉南二街 8 号 A 幢三楼 会议室。 （三）召开方式：采取现场投票与网络投票相结合。 网络投票：广东泰恩康医药股份有限公司（以下简称"公司"）通过深圳证券 交易所交易系统和互联网投票系统向股东提供网络形式的投票平台。 （四）召集人：董事会 （五）主持人：董事长郑汉杰先生 （六）本次会议的召集、召开与表决程序符合《中华人民共和国公司法》 $$\mathbb{C}$$ 市公司股东会规则》等法律、法规、规范性文件以及《公司章程》《股东大会议 事规则》的规定。 （七）会议出席情况 通过现场和网 ...

Group 1 - The legal opinion letter confirms the legitimacy of the 2025 First Extraordinary General Meeting of Guangdong Tai'enkang Pharmaceutical Co., Ltd. [1][3] - The meeting was convened on August 20, 2025, following the approval of the board of directors on August 4, 2025, with proper notification to shareholders [2][3] - A total of 227 participants attended the meeting, representing 42,134,395 shares, which is 9.9488% of the total shares as of the record date [3][4] Group 2 - The meeting was chaired by Chairman Zheng Hanjie, and the procedures followed were in accordance with the Company Law and relevant regulations [3][5] - Voting was conducted through both on-site and online methods, with results announced immediately after the voting process [5][6] - The resolutions passed included significant support from shareholders, with over 99.9% approval for key proposals [6][7] Group 3 - The legal opinion concludes that the meeting's convening, procedures, and voting were all compliant with applicable laws and the company's articles of association, rendering the resolutions valid [7][8] - The legal opinion letter is to be submitted alongside other disclosure materials related to the meeting [7][9]

Meeting Announcement - The company will hold its second extraordinary general meeting of shareholders on September 10, 2025, as approved by the board of directors on August 19, 2025 [2][3] - The meeting will take place at 15:00 local time, with network voting available from 9:15 to 11:30 on the same day [2][3] Voting Procedures - Shareholders can choose between on-site voting and network voting, but must select only one method [3][4] - All ordinary shareholders registered by the close of trading on the registration date are entitled to attend and vote at the meeting [3][4] Agenda Items - The meeting will discuss proposals including the establishment and revision of internal control management systems and a management method to prevent the controlling shareholder and related parties from occupying company funds [3][4][11] Registration Details - Registration for corporate shareholders requires documentation including a business license copy and a representative's ID, while individual shareholders must present their shareholding proof and ID [5][6] - Registration for on-site attendance will occur on September 5, 2025, from 9:00 to 11:00 and 14:30 to 17:00 [5][6] Network Voting Instructions - The company provides a network voting platform through the Shenzhen Stock Exchange, with specific procedures outlined for participation [6][7]

Market Overview - The Hong Kong stock market experienced a narrow downward trend, with the Hang Seng Index down 0.1% at 25,140.96 points, the Hang Seng Tech Index down 0.51% at 5,513.04 points, and the National Enterprises Index down 0.32% at 8,984.22 points [1] - Major technology stocks mostly declined, with Xiaomi and Baidu dropping over 2%, and Meituan down 1.4% [1] - Pharmaceutical stocks surged, particularly internet healthcare stocks, with Dingdang Health rising over 22% and Ping An Good Doctor up over 10% [1] - Infrastructure stocks strengthened, especially high-speed rail stocks, with China CNR Corporation increasing over 5% [1] - Other sectors such as home appliances, oil, rare earths, and electricity were active, while entertainment, lithium battery, automotive, robotics, and gold stocks mostly weakened [1] Company News - Baidu Group reported Q2 revenue of 32.7 billion yuan, a year-on-year decrease of 4%, while net profit increased by 33% to 7.322 billion yuan [2] - Wynn Macau's revenue for the first half was approximately 13.63 billion HKD, down 7.5%, with net profit falling 85.5% to about 231 million HKD [3] - Huazhu Group's revenue for the first half was approximately 11.8 billion HKD, up 3.5%, with net profit increasing by 41.3% to about 2.4 billion HKD [4] - China Evergrande's listing status will be canceled on August 25, while China State Construction International reported a revenue of approximately 566.43 billion HKD, up 0.1%, and a net profit of about 52.59 billion HKD, up 5.1% [5] - Hong Kong and China Gas reported a revenue of 27.514 billion HKD for the first half, up 0.07%, with net profit decreasing by 2.5% to 2.964 billion HKD [5] Institutional Insights - CITIC Securities indicated that the half-year report performance period will be a crucial point for the continuation of the Hong Kong stock market, with a shift from liquidity-driven to performance-driven and policy validation phases expected [6] - Zhongtai Securities noted that the Hong Kong market is likely to benefit from the acceleration of AI commercialization and continued inflow of southbound funds, with significant growth potential in AI technology and new consumption sectors [6] - Industrial Securities highlighted that the Hong Kong market is experiencing a phase of volatility and differentiation, with a focus on mid-year performance and cost-effectiveness [6] - Zhongtai International reported a record net inflow for the Hong Kong Stock Connect, with 6.03 billion USD flowing into the Chinese stock market in July, indicating strong domestic investor sentiment [7]

Economic Overview - The overall economic operation of the province is stable from January to July, with a year-on-year industrial added value growth of 3.9% [1] - High-tech manufacturing industry shows a significant growth of 7.8% [1] Industrial Performance - Mining industry increased by 10.9%, while manufacturing and electricity, heat, gas, and water production and supply industries grew by 3.0% and 1.1% respectively [1] - Among 40 major industrial categories, 23 experienced year-on-year growth, representing a growth rate of 57.5% [1] - Notable growth in chemical fiber manufacturing (9.3 times), and double-digit growth in several sectors including pharmaceutical manufacturing and electrical machinery [1] Investment Trends - Manufacturing investment increased by 22.8%, with high-tech manufacturing investment rising by 37.0% [2] - First industry investment decreased by 7.1%, while second industry investment grew by 7.9% [2] - Construction project investment increased by 1.8%, with projects over 100 million yuan growing by 6.0% [2] Consumer Market - Retail sales of consumer goods reached 597.72 billion yuan, with a year-on-year growth of 5.5% [2] - Significant growth in essential goods, with food retail sales increasing by 17.0% and daily necessities by 12.9% [2] - Upgraded products like smartphones and wearable devices saw substantial sales growth, with smartphones increasing by 130% [2] Trade Performance - Total import and export value reached 437.61 billion yuan, with exports growing by 13.6% [3] - Agricultural product exports increased by 9.1%, while steel and electromechanical products also saw growth [3] Price Trends - A slight decline in consumer prices and a decrease in industrial producer prices were noted [4]

Group 1: Company Insights - Huafeng Aluminum achieved a total revenue of 5.964 billion yuan in the first half of 2025, a year-on-year increase of 20.87%, but profit growth was limited to 2.02% due to the cancellation of export tax rebates and intensified market competition [1] - Unigroup Guowei's revenue and net profit from its subsidiary Shenzhen Guowei Electronics significantly increased, with a growth rate of approximately 18%-20% for simulation chips, which account for 40%-50% of its revenue [2] - Pro Pharmaceutical expects its CDMO business to reach a scale of 6-7 billion yuan by 2030, with a projected gross margin improvement to 45%-55% due to project structure optimization [3] - Nopson aims to enhance organizational efficiency and optimize processes to control costs, focusing on expanding its blueberry sales through K channels and improving brand visibility [4] - Shanjin International reported a decrease in gold production in the first half of 2023 but is implementing measures to recover production in the second half, with a stable dividend policy and a projected contribution of 95.87% to net profit from gold-producing mines in 2024 [5] Group 2: Market Trends and Strategies - Huafeng Aluminum is responding to slowing demand in the automotive sector by developing high-value-added new products and accelerating the construction of its Chongqing Phase II project [1] - Unigroup Guowei is focusing on the high-end AI and visual perception chip market, with a stable order flow and plans to enhance its eSIM chip market share, contingent on policy support [2] - Pro Pharmaceutical's growth in the CDMO sector is driven by efficiency, cost, service, delivery, and quality systems, with a significant increase in R&D personnel to support its expansion [3] - Nopson is strategically positioning its operations in Laos for blueberry production, aiming to increase export proportions to Southeast Asia [4] - Shanjin International's future gold production growth is expected to come from the Osino project and external acquisitions, with a strategic focus on resource management [5]

Core Viewpoint - The recent financial report of Jianmin Group shows a decline in revenue and net profit for the first half of 2025, indicating challenges in the pharmaceutical market and increased operational costs [1][3]. Financial Performance - Total revenue for the first half of 2025 was 1.805 billion yuan, a decrease of 10.2% year-on-year [1]. - Net profit attributable to shareholders was 221 million yuan, down 7.83% year-on-year [1]. - In Q2 2025, total revenue was 913 million yuan, a decline of 12.21% year-on-year, with net profit of 110 million yuan, down 21.01% year-on-year [1]. - The gross margin improved to 59.44%, an increase of 38.26% year-on-year, while the net margin was 12.32%, up 2.73% year-on-year [1]. - The total of selling, administrative, and financial expenses reached 869 million yuan, accounting for 48.17% of total revenue, an increase of 34.66% year-on-year [1]. Key Financial Ratios - Earnings per share (EPS) decreased to 1.46 yuan, down 6.41% year-on-year [1]. - The company's net asset per share increased to 16.41 yuan, up 9.12% year-on-year [1]. - Operating cash flow per share remained stable at 0.36 yuan, with a slight increase of 0.84% year-on-year [1]. Changes in Financial Items - Accounts receivable decreased by 14.4% to 907 million yuan, while cash and cash equivalents fell by 8.36% to 171 million yuan [3]. - Short-term borrowings decreased significantly by 60.96% due to repayments by commercial subsidiaries [3]. - The company experienced a substantial increase in financial expenses, up 351.65%, attributed to changes in accounting for discounted bills [3]. Business Model and Strategy - The company relies heavily on marketing-driven performance, with a return on invested capital (ROIC) of 15.14% for the previous year, indicating strong capital returns [4]. - The company is focusing on optimizing its marketing assessment system and enhancing digital capabilities to improve sales performance [7]. Market Outlook - Analysts expect the company's performance in 2025 to reach 448 million yuan, with an average EPS forecast of 2.92 yuan [5]. - The company has seen a positive trend in sales of certain products, such as Longmu Bone Strengthening Granules and Jianpi Shengxue Granules, despite market challenges [7].

Company Overview - Zhongsheng Pharmaceutical closed at 22.79 yuan on August 20, down 1.04 yuan, a decrease of 4.36% from the previous trading day [1] - The opening price was 23.39 yuan, with a high of 24.34 yuan and a low of 22.50 yuan, and the trading volume reached 661,194 hands with a transaction amount of 1.537 billion yuan [1] Business Operations - Zhongsheng Pharmaceutical is primarily engaged in the manufacturing of pharmaceuticals, focusing on the research, production, and sales of traditional Chinese medicine, chemical drugs, and biological drugs [1] - The company's product range covers multiple therapeutic areas, including cardiovascular, anti-infection, digestive system, and respiratory system [1] Market Activity - On the morning of August 20, Zhongsheng Pharmaceutical experienced a rapid rebound, with a rise of over 2% within 5 minutes, peaking at 24.01 yuan [1] - The net outflow of main funds on that day was 120.6993 million yuan, while the net inflow over the past five days was 14.899 million yuan [1]

Core Viewpoint - The company, 泰恩康, announced the convening of its fifth board meeting to review the 2025 semi-annual report and its summary, indicating ongoing corporate governance and financial transparency [1]. Financial Performance - For the year 2024, 泰恩康's revenue composition is as follows: pharmaceutical agency accounts for 61.1%, pharmaceutical manufacturing for 37.28%, pharmaceutical technology services for 1.51%, and other businesses for 0.12% [1]. - The current market capitalization of 泰恩康 is 15.4 billion yuan [1].

Group 1 - The company Nanjing Xinbai plans to reduce its repurchased shares by up to 6 million shares, accounting for 0.45% of its total share capital, through centralized bidding trading starting 15 trading days after the announcement until September 26, 2025 [1] - The company will adjust the number of shares to be reduced if there are changes in the number of shares due to stock dividends or capital reserve transfers during this period [1] - After the sale of the repurchased shares, the remaining shares will be arranged for cancellation as per the repurchase plan [1] Group 2 - For the year 2024, the revenue composition of Nanjing Xinbai is as follows: health and elderly care industry 31.77%, pharmaceutical manufacturing 24.3%, professional technical services 17.41%, medical services 13.59%, and commodity circulation 6.14% [1] - As of the report, the market capitalization of Nanjing Xinbai is 11.9 billion yuan [1]